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Abstract
A chimeric antigen receptor (CAR) that responds to transforming growth factor beta (TGF-b) ena-
bles the engineering of T cells that convert this immunosuppressive cytokine into a potent T-cell
stimulant. However, clinical translation of TGF-b CAR-T cells for cancer therapy requires the ability
to productively combine TGF-b responsiveness with tumor-targeting specificity. Furthermore, the
potential concern that contaminating, TGF-b–producing regulatory T (Treg) cells may preferentially
expand during TGF-b CAR-T cell manufacturing and suppress effector T (Teff) cells demands care-
ful evaluation. Here, we demonstrate that TGF-b CAR-T cells significantly improve the anti-tumor
efficacy of neighboring cytotoxic T cells. Furthermore, the introduction of TGF-b CARs into mixed
T-cell populations does not result in the preferential expansion of Treg cells, nor do TGF-b CAR-
Treg cells cause CAR-mediated suppression of Teff cells. These results support the utility of incor-
porating TGF-b CARs in the development of adoptive T-cell therapy for cancer.
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1 | INTRODUCTION
Adoptive T-cell immunotherapy has produced promising results in
the treatment of advanced B-cell malignancies, leading to the
approval of anti-CD19 chimeric antigen receptor (CAR)-T cell thera-
pies by the United States Food and Drug Administration in 2017.1,2
However, successful treatment of solid tumors has been more elu-
sive, in part due to the highly immunosuppressive nature of tumor
microenvironments.3 One prominent mechanism by which tumor
cells evade immune surveillance is the secretion of transforming
growth factor beta (TGF-b).4 TGF-b has been shown to not only
directly suppress T-cell effector function5,6 but also drive T-cell
differentiation into the regulatory phenotype.7 Regulatory T (Treg)
cells are, in turn, able to produce TGF-b and further promote tumor
tolerance.8,9
Because of its suppressive role in the tumor microenvironment,
TGF-b has been targeted in several studies seeking to boost anti-
tumor immunity. For example, monoclonal antibodies targeting TGF-b
and TGF-b receptor chain 2 (TGFBR2) have been extensively studied
in preclinical and early-phase clinical studies.10 Other studies
have more specifically targeted TGF-b signaling within the tumor
microenvironment with a TGF-b dominant-negative receptor (TGF-b
DNR), which renders transduced tumor-specific T cells unresponsive to
TGF-b.11–13 We recently described a novel CAR that responds to TGF-
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b (TGF-b CAR), demonstrating the ability to not only inhibit endoge-
nous TGF-b signaling in T cells but also convert TGF-b into a potent T-
cell stimulant.14 Indeed, TGF-b CAR-T cells proliferate robustly and
secrete Th1 cytokines in the presence of TGF-b.
Here, we demonstrate that TGF-b CAR-T cells can also protect
neighboring immune cells from the suppressive effects of TGF-b by
enabling tumor-targeted CD81 T cells to retain cytolytic activity in the
presence of TGF-b, and by discouraging CD41 T cells from TGF-b–
induced Treg differentiation. Furthermore, we show that “contaminat-
ing” Tregs within bulk T cells transduced with the TGF-b CAR are not a
liability, as TGF-b CAR-transduced Tregs do not preferentially expand
or exert detrimental immune suppression. Taken together, our results
suggest that the TGF-b CAR can safely and effectively boost the anti-
tumor efficacy of T-cell therapy.
2 | MATERIALS AND METHODS
2.1 | DNA constructs
TGF-b–specific CARs with short and long spacers (IgG4 hinge and
IgG4 hinge-CH2-CH3, respectively), as well as the scFv-less CAR, were
constructed as previously described.14 The CARs contain the CD28
transmembrane domain, the CD28 cytosolic tail with GG mutations to
enhance CAR surface expression,15 and the CD3f cytosolic domain.
The NY-ESO-1 TCR was a gift from Dr. Antoni Ribas (University of Cal-
ifornia, Los Angeles).16 The CD19- and CD20-binding CARs contain
the 4-1BB and CD3f intracellular domains as previously described.17
The TGF-b DNR encodes the first 199 amino acids of TGFBR2. All
receptors were linked by the “self-cleaving” T2A sequence to a trun-
cated epidermal growth factor receptor (EGFRt), a non-signaling trans-
duction marker that also facilitates sorting of CAR-expressing cells.18
2.2 | Cell lines
Raji cells and TM-LCLs, an Epstein-Barr virus-transformed lymphoblastoid
cell line, were gifts from Dr. Michael Jensen (Seattle Children’s Research
Institute). M407 human melanoma cells stably transfected with a nuclear-
localizing red fluorescent protein (RFP) were a gift from Dr. Antoni Ribas.
EGFP NFAT reporter Jurkat cells were a gift from Dr. Arthur Weiss (Uni-
versity of California, San Francisco). Cell lines were maintained in com-
plete RPMI (RPMI1640 (Lonza)110% heat-inactivated FBS (Gibco)).
2.3 | Generation of CAR-expressing primary
human T cells
Lentivirus was produced as previously described.17 CD41 or CD81 T
cells were isolated with the RosetteSep CD41 or CD81 Human T-Cell
Enrichment Cocktail (STEMCELL Technologies) from healthy donor
whole blood obtained from the UCLA Blood and Platelet Center. T cells
were then stimulated with CD3/CD28 Dynabeads (Thermo Fisher Sci-
entific) at a 1:1 cell:bead ratio for 2 days and transduced with lentivirus
at a multiplicity of infection (MOI) of 1.5–3. T cells were cultured in
complete RPMI and fed 50 U/mL IL-2 (Thermo Fisher Scientific) and 1
ng/mL IL-15 (Miltenyi Biotec) every 2–3 days. Dynabeads were
removed after 9 days of culture. Transduced cells were enriched by
magnetic bead-based sorting (Miltenyi Biotec) and kept in culture with
IL-2/IL-15 supplementation every 2–3 days.
For experiments involving Treg cells, CD41 T cells isolated as men-
tioned above were stained with fluorescently conjugated anti-CD4
(clone RPA-T4, BioLegend), anti-CD25 (clone BC96, BioLegend), and
anti-CD127 (clone A019D5, BioLegend) antibodies, and then Treg
(CD41CD25hiCD127–) and non-Treg (CD41CD25–) fractions were
enriched on a BD FACSAria II cell sorter. Treg cells were stimulated
with CD3/CD28 Dynabeads at a 1:1 cell:bead ratio for 2 days and then
transduced with lentivirus at an MOI of 5. Tregs were cultured in com-
plete RPMI supplemented with 100 nM rapamycin and fed 300 U/mL
IL-2 every 2–3 days. Dynabeads were removed after 10 days of cul-
ture, and cells were subsequently re-stimulated with Dynabeads at a
2:1 cell:bead ratio. Cells were then cultured in complete RPMI without
rapamycin, and IL-2 was supplemented every 2–3 days. In some experi-
ments, cultures were also supplemented with 5 ng/mL TGF-b after re-
stimulation. Dynabeads were removed on day 20 or 21 of culture. Fol-
lowing Dynabead removal, Tregs were rested in IL-2–free medium for
24 hr prior to use in downstream experiments.
A note on TGF-b concentration used in this study: To our knowl-
edge, there has been no report of typical active TGF-b concentrations
found in tumor tissue. Instead, published studies have relied on ELISA or
receptor binding assays performed on blood plasma, with widely varying
results (0.5–25 ng/mL in human plasma).19 It has been shown that TGF-
b concentrations are significantly higher in plasma samples from cancer
patients compared to healthy controls,20 but the precise level of active
TGF-b at tumor local environments remains unknown. Active TGF-b
concentrations are expected to be higher at tumor sites than in plasma,
as solid tumors are known to secrete TGF-b, and latent forms of TGF-b
(produced by either tumor or other cell types) are known to be acti-
vated by tumor-associated metalloproteases.21 Based on available infor-
mation, we have chosen to use 5 ng/mL as the standard TGF-b input
concentration because (a) it is within the reported range of physiological
TGF-b concentrations, (b) it is consistent with the conditions used by
various research groups studying TGF-b signaling in T cells,12,22–24 and
(c) this input level has been verified to induce endogenous TGF-b sig-
naling and functional defects in primary human T cells.14
2.4 | T-cell cytotoxicity assays
An automated live-cell imaging system (IncuCyte, Essen BioScience)
was used to evaluate T-cell cytotoxicity dynamics against the adherent
NY-ESO-11 RFP1 M407 cell line, following a previously described pro-
tocol.25 RFP1 M407 cells were seeded overnight at 104 cells/100 lL/
well in flat-bottom 96-well plates. The next day, T-cell mixtures (2.5 3
104 CD81 T cells expressing the NY-ESO-1 TCR plus 2.5 3 104 CD41
T cells expressing the indicated constructs) were applied in 100 lL vol-
umes to target cells in triplicate, with or without 5 ng/mL TGF-b. In
order to observe a clear TGF-b–induced defect in T-cell cytotoxicity, T
cells were collected 48 hr after the first challenge and applied to a new
batch of tumor cells (seeded the night before) for a second challenge,
with or without 5 ng/mL TGF-b. The amount of red fluorescence,
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measured every 2 hr and normalized to the time 0 fluorescence, indi-
cated the proportion of live tumor cells remaining. Log-linear models
were applied to cytotoxicity dynamics data using R 3.3.2 software.
An electrical impedance-based tumor cell culture system (xCELLi-
gence, ACEA Biosciences) was used to evaluate T-cell cytotoxicity
dynamics against the CD201 Raji cell line. Though normally suspension
cells, Raji cells were immobilized onto 96-well, electrode-bottomed
plates pre-coated with anti-CD40 antibodies at 3 3 104 cells/100 lL/
well. The next day, T-cell mixtures (3 3 104 CD81 T cells expressing
the CD20 CAR plus 3 3 104 CD41 T cells expressing the indicated
constructs) were added in quadruplicate, with or without 5 ng/mL
TGF-b. Forty-eight hours later, T cells were collected and applied to a
new batch of tumor cells (seeded the night before) for the second chal-
lenge, with or without 5 ng/mL TGF-b. The cell index, a measure of
electrode impedance correlating to Raji-cell viability, was measured
every 15 min, normalized to the time 0 cell index, and used as an indi-
cator for the proportion of live tumor cells remaining. Log-linear models
were applied to cytotoxicity dynamics data using R 3.3.2.
2.5 | Treg cell induction assay
Previously unstimulated CD41 T cells were seeded in OKT3-coated 96-
well U-bottom plates at 5 3 104 cells/100 lL/well with 20 U/mL IL-2, 1
lg/mL CD28 agonist antibody (clone CD28.2, BioLegend), and 0 or 5
ng/mL TGF-b. After 1 day, the samples were supplemented with donor-
matched CD41 T cells expressing the indicated constructs. The supple-
mentary cells were stained with 0.5 lM CellTrace Violet (CTV) and
added at 5 3 104 cells/50 lL/well in media supplemented with 20 U/
mL IL-2, 1 lg/mL CD28 agonist antibody, and 0 or 5 ng/mL TGF-b. On
day 5 of the assay, cells were stained with anti-CD25 antibody, fixed
and permeabilized (True-Nuclear Transcription Factor Buffer Set, BioLe-
gend), and stained with anti-FOXP3 antibody (clone 206D, BioLegend).
2.6 | NFAT reporter assays
NFAT EGFP reporter Jurkat cells transduced with the TGF-b CAR
were seeded at 5–10 3 104 cells/100 lL/well in triplicate in 96-well
plates, with indicated levels of human TGF-b or human latent latency
associated peptide (LAP)-bound TGF-b (BioLegend). Reporter induction
was assessed by flow cytometry after 17 hr at 378C.
2.7 | Treg suppression assays
In experiments testing TCR-mediated suppression, CD41CD252 Teffs
that were never activated in vitro were stained with 1.25 lM CFSE.
CFSE-labeled Teffs were seeded in OKT3-coated 96-well U-bottom
plates at 5 3 104 cells/well with 1 lg/mL CD28 agonist antibody
(clone CD28.2, BioLegend), and 0 or 5 ng/mL TGF-b. Tregs were added
to each well at a 1:1 Treg:Teff ratio.
In experiments testing CAR-mediated suppression, CD19 CAR-
transduced CD41CD25– Teffs were stained with 1.25 lM CFSE, and
Tregs were stained with 1.25 lM CTV. CFSE-labeled Teffs were
seeded in 96-well U-bottom plates at 5 3 104 cells/well with 1 3 105
irradiated TM-LCL cells and 0, 5, or 10 ng/mL TGF-b. CTV-labeled
Tregs were added to each well at a 1:1 Treg:Teff ratio.
2.8 | Statistical analyses
Statistical tests were performed in Excel and R 3.3.2. Student’s t tests
with unequal variances were used to compare continuous variables
between two groups, with the Sidak correction for multiple compari-
sons. Analyses of variance (ANOVAs) were used to assess variation
among more than two groups, with post-hoc pairwise comparisons by
Dunnett’s test when contrasting multiple factors with a single standard
factor (Figure 1c,d) or by Tukey’s test when contrasting multiple factors
with more than one standard factor (Figure 2b). All tests were two-
tailed with a hypothesis-specific family alpha level of 0.05.
3 | RESULTS
3.1 | TGF-b CAR-T cells protect tumor-targeting
T cells from TGF-b–mediated immunosuppression
An important advantage of the TGF-b CAR is its ability to trigger effec-
tor functions that interface with other immune cells, a feature not avail-
able to the TGF-b DNR. To characterize this property, a series of co-
culture assays were performed to investigate whether TGF-b CAR-T
cells can indeed support the anti-tumor immunity of nearby T cells.
First, we found that CD41 TGF-b CAR-T cells significantly reduced the
ability of TGF-b to impair the cytotoxicity of tumor-targeting CD81 T
cells. CD81 T cells engineered to express either an NY-ESO-1 TCR or a
CD20 CAR were co-incubated with donor-matched CD41 T cells
expressing one of three constructs: (a) the TGF-b CAR; (b) an scFv-less
CAR, which is identical to the TGF-b CAR except it lacks the scFv
domain and thus cannot bind TGF-b; or (c) the TGF-b DNR. Each T-cell
mixture was challenged with two rounds of cognate tumor cells (i.e.,
NY-ESO-11 M407 melanoma or CD201 Raji, neither of which shows
changes in growth rate in response to TGF-b alone) (Figure 1a,b). In this
co-culture, only the CD81 T cells have tumor-recognition capability,
since the CD41 T cells do not express a tumor-antigen–specific recep-
tor. Unique among the four T-cell mixtures tested, samples containing
TGF-b CAR-T cells showed no significant change in tumor-killing capa-
bility despite the presence of TGF-b, resulting in significantly lower
tumor-cell survival compared to samples expressing the scFv-less CAR
or DNR (Figure 1c–f). Cell-killing kinetics were quantified by fitting the
time-course data to log-linear models, which proportionally relate the
rate of killing to the number of tumor cells remaining (Figure 1e,f).
The results indicated that for both NY-ESO-1 TCR- and CD20 CAR-
expressing cytotoxic T cells, pairing with CD41 TGF-b CAR-T cells
resulted in the least amount of TGF-b–induced loss of cytotoxicity and
the highest killing rate in the presence of TGF-b (Table 1).
3.2 | TGF-b CAR-T cells suppress TGF-b–induced
differentiation into Treg phenotype
We next evaluated the impact of TGF-b CAR-T cells on the differentia-
tion of naïve T cells into the Treg phenotype, which suppresses tumor
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rejection.3 TGF-b has been shown to promote Treg differentiation,7
and this behavior was confirmed through the following co-culture
experiment: previously unactivated CD41 T cells were primed with IL-
2, anti-CD28, and immobilized OKT3, with or without TGF-b. One day
later, donor-matched, CTV dye-labeled T cells expressing the scFv-less
CAR, TGF-b DNR, or TGF-b CAR were added (Figure 2a). After 4 days
FIGURE 1 TGF-b CAR-T cells reduce TGF-b–mediated suppression of CD81 T-cell cytotoxicity. (a) Schematic of assay setup. CD41 T cells
expressing an scFv-less CAR, TGF-b DNR, or TGF-b CAR were co-cultured with donor-matched CD81 T cells expressing an NY-ESO-1 TCR
or CD20 CAR, and challenged twice with cognate tumor cells (NY-ESO-11 M407 or CD201 Raji, respectively) in the presence or absence of
TGF-b. (b) In the absence of T cells, TGF-b does not impact the expansion of NY-ESO-11 M407 and CD201 Raji cells within the time-scale
of the assay. The % of tumor cells remaining relative to the number of tumor cells at time 0 is shown. NY-ESO-11 M407 melanoma cells
were cultured for 29.5 hr and CD201 Raji cells were cultured for 24 hr. (c,d) Percent of tumor cells remaining quantified at the end of the
second challenge. (e,f) Time-courses of the % tumor cells remaining during the second challenge, overlaid with log-linear fits of tumor-cell
killing dynamics. Shading around the line indicates the 99% confidence band of the fit. Model parameters are presented in Table 1. For visi-
bility, every seventh time point is shown in (f). Averages of (c,e) triplicates or (d,f) quadruplicates are shown with error bars representing61
standard deviation (SD). Statistics for TGF-b–dependent changes are calculated by two-tailed Student’s t tests with the Sidak correction for
multiple comparisons. ANOVAs of TGF-b–exposed cell mixtures yielded significant variation among the different mixtures with (c) F56.8,
df53, p< .05; and (d) F543.6, df53, p< .001. * p< .05, ** p< .01, and *** p< .001
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of co-culture, a significant increase in the proportion of dye-negative
CD251FOXP31 cells was observed specifically in the presence of
TGF-b, and this Treg differentiation could not be prevented by the
addition of T cells expressing the scFv-less CAR or the DNR (Figure
2b). In contrast, T cells expressing TGF-b CAR blocked Treg
differentiation of nearby (CTV2) T cells, resulting in no significant
increase in the proportion of Treg cells even in the presence of TGF-b
(Figure 2b,c). Altogether, the TGF-b CAR-T cells are superior to TGF-b
DNR-expressing T cells in restricting the ability of TGF-b to orchestrate
immunosuppressive functions.
FIGURE 2 TGF-b CAR-T cells reduce the induction of Treg differentiation. (a) Schematic of assay setup. Previously unactivated CD41
T cells were cultured in OKT3-coated wells with IL-2 and anti-CD28, with or without TGF-b for 24 hr. The wells were subsequently supple-
mented with donor-matched, CTV-stained CD41 T cells expressing the scFv-less CAR, TGF-b DNR, or TGF-b CAR. The emergence of Treg
cells was quantified 4 days later. (b) Induction of CD251FOXP31 subpopulations in CD41 T cells in cultures with or without TGF-b, after
the addition of CD41 T cells expressing the different synthetic receptors. Averages of triplicates are shown with error bars representing61
SD. Statistics for TGF-b–dependent changes are calculated by two-tailed Student’s t test with the Sidak correction for multiple comparisons.
ANOVAs of TGF-b–exposed cell mixtures yielded significant variation among the different mixtures with F522.7, df53, p< .001. Pairwise
contrasts are evaluated post-hoc by Tukey’s test. * p< .05, ** p< .01, and *** p< .001. (c) Representative CD25 versus FOXP3 scatters are
shown for the viable/singlet/CTV– gated population
TABLE 1 Rate constants for tumor-cell killing dynamics
Kill rate constants6 SE (31022/hr)
CD81 cell line CD41 cell line No TGF-b 5 ng/mL TGF-b Difference
NY-ESO-1 TCR scFv-less CAR 3.1360.09 1.2160.13 1.926 0.09
TGF-b DNR 2.0360.05 1.3360.06 0.716 0.04
TGF-b CAR 2.9660.11 2.3060.15 0.656 0.11
CD20 CAR scFv-less CAR 7.6660.04 4.1060.06 3.566 0.04
TGF-b DNR 8.2660.08 5.1860.11 3.086 0.7
TGF-b CAR 9.4160.10 6.6860.14 2.736 0.09
Log-linear models, which state that the rate of killing is proportional to the number of remaining tumor cells, were applied to tumor-cell death curves
(Figure 1e,f) to estimate the TGF-b–mediated difference in cytotoxicity rate constants of various T-cell mixtures. All model parameters were estimated
with high statistical confidence (p<1027). SE, standard error.
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3.3 | TGF-b CAR does not respond to latent form
of TGF-b
A potential concern around the clinical translation of TGF-b CAR-T
cells is whether they would be non-specifically activated in normal tis-
sue, resulting in systemic toxicity. All three TGF-b isoforms—TGF-b1,
TGF-b2, and TGF-b3—are produced as precursor molecules and are
generally found in the latent form bound to a LAP.26 Activation of the
TGF-b homodimer requires the presence of metalloproteases or
mechanical forces to induce the dissociation of the LAP. Therefore,
only the latent and not the active form of TGF-b is found at high levels
in blood serum.26 We have confirmed that the TGF-b CAR does not
respond to the latent form of TGF-b (Figure 3), thus reducing the risk
of non-specific, systemic activation of TGF-b CAR-T cells in non-tumor
tissue. Coupled with our previously reported observation that TGF-b
CAR activation is dependent on TGF-b dose input,14 these results
strongly support that TGF-b CAR-T cells would only be activated in
areas of high TGF-b local concentration, such as solid tumor
microenvironments.14
3.4 | TGF-b CAR expression in Treg cells does not
trigger CAR-mediated suppression
At present, CAR-T cell therapy is a personalized medical treatment,
with unique cell products produced for each patient.27 Although a vari-
ety of cell-manufacturing starting materials are used, including periph-
eral blood mononuclear cells (PBMCs), CD8-sorted cells, or T cells
sorted for either naive or memory phenotypes,28–31 most manufactur-
ing processes do not specifically deplete Treg cells. Since activated
Treg cells secrete TGF-b,8 and TGF-b CAR signaling promotes robust
T-cell expansion,14 concerns arise of whether TGF-b CAR expression
would inadvertently enrich Treg cells in a T-cell product, and whether
TGF-b CAR-Treg cells would cause counterproductive CAR-mediated
immunosuppression.
To evaluate the effect of TGF-b CAR expression specifically on
Tregs, experiments were performed using FACS-sorted CD41/CD25hi/
CD127– cells (Figure 4a,b), which have been shown to be enriched in
the Treg phenotype.32 Interestingly, unlike non-Tregs,14 Treg cells con-
sistently showed more efficient surface presentation of the TGF-b
CAR containing a long (229-amino acid) extracellular spacer compared
to an otherwise identical CAR containing a short (12-amino acid) spacer
(Figure 4c). Therefore, all subsequent experiments in Treg cells were
performed with the long TGF-b CAR.
The most definitive marker of Treg phenotype—FOXP3—is an
intracellular protein that cannot be used for live-cell sorting based on
surface antibody staining. As a result, the expanded CD41/CD25hi/
CD127–-sorted cell population included a residual fraction of FOXP32
cells, regardless of whether the cells had been transduced with the
TGF-b CAR (Figure 5a). Consistent with previous observations (Figure
2b), the addition of TGF-b resulted in an increase in FOXP3 expression
in untransduced, CD41/CD25hi/CD1272-sorted cells, confirming that
TGF-b promotes the differentiation of non-Treg cells into the Treg
phenotype (Figure 5a,b). In contrast, TGF-b–mediated induction of
FOXP3 expression was not observed in CD41/CD25hi/CD1272-sorted
cells transduced with the TGF-b CAR. These results indicate that TGF-
b CAR expression does not promote preferential expansion of FOXP31
Tregs over non-Tregs. Instead, CAR expression appears to suppress the
overall frequency of FOXP31 Tregs in mixed T-cell populations treated
with TGF-b (Figure 5b), likely by preventing the differentiation of non-
Treg cells into the regulatory phenotype as previously observed in Fig-
ure 2. We expect the suppression of FOXP3 upregulation to be specific
to TGF-b CARs as opposed to CARs in general, since CD19 CAR and
scFv-less CAR-T cells are neither activated by TGF-b, nor do they
exhibit changes in endogenous TGF-b signaling compared to mock-
transduced T cells.14
We next evaluated whether Treg cells activated through TGF-b
CAR signaling would exert suppressive effects on nearby Teff cells. Co-
cultures were set up with CFSE-labeled CD41CD252 Teff cells, anti-
CD3, and anti-CD28, with or without TGF-b CAR-transduced CD41/
CD25hi/CD127–-sorted cells (Figure 6a). In such co-cultures, anti-CD3
and anti-CD28 served to activate both Treg and Teff cells by triggering
TCR signaling. CFSE dilution in Teff cells was quantified after 96 hr of
co-culture, with results indicating clear suppression of Teff proliferation
in the presence of CD41/CD25hi/CD1272-sorted cells (Figure 6a),
confirming this population contained sufficient numbers of Treg cells to
effectively suppress Teff proliferation upon TCR-mediated T-cell acti-
vation. Notably, addition of TGF-b did not enhance suppression medi-
ated by TGF-b CAR-transduced Treg cells (Figure 6a). Furthermore,
TGF-b CAR-transduced Tregs were no more suppressive than
FIGURE 3 TGF-b CAR-T cells do not respond to the latent form
of TGF-b. Soluble TGF-b in the active or latent (LAP-bound) form
was added at the specified concentrations to a Jurkat T-cell line
that stably expresses an EGFP reporter driven by an NFAT-
responsive promoter. EGFP expression was quantified by flow
cytometry after 17 hr. The TGF-b CAR-T cells are only activated
by the active form of TGF-b
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untransduced Tregs (Figure 6b). These results indicate that the TGF-b
CAR itself does not boost the suppressive capacity of Treg cells.
To determine whether CAR-mediated (as opposed to TCR-medi-
ated) Treg activation would similarly suppress CAR-Teff proliferation, a
CD19 CAR was introduced into CD41 Teff cells, and co-cultures were
set up with CFSE-labeled CD19 CAR-Teff cells and irradiated parental
(CD191/OKT32) TM-LCL target cells, with or without CTV-labeled
TGF-b CAR-transduced Treg cells (Figure 7a). In this system, the Teff
and Treg cells were separately activated via their CARs by CD19 and
TGF-b, respectively, thus enabling specific inquiry into the effect of
CAR activation on the Treg cells’ suppressive potential. CTV dilution in
Tregs (Figure 7b) and CFSE dilution in Teffs (Figure 7c) were quantified
after 72 hr of co-culture. Flow cytometry analysis revealed that TGF-b
CAR-transduced Treg cells, but not untransduced Treg cells, divided in
response to TGF-b addition (Figure 7b,c), thus confirming TGF-b CAR
signaling. However, this Treg population was unable to suppress Teff
proliferation (Figure 7d), indicating that CAR-activated Tregs do not
exert significant suppressive influence on nearby Teff cells.
Taken together, these results indicate that even if the starting pop-
ulation for therapeutic T-cell manufacturing contains Treg cells,
FIGURE 4 The TGF-b CAR with a long spacer exhibits more efficient surface presentation in Tregs than the TGF-b CAR with a short
spacer. (a) Representative flow plots depicting gating strategy for the sorting of CD41/CD25hi/CD127– Tregs. (b) Representative flow plots
depicting surface marker expression of cells immediately after sorting. (c) TGF-b CAR-transduced CD41/CD25hi/CD127–-sorted cells were
stained for surface expression of FLAG-tagged CARs. Averages of triplicates are shown, with error bars representing61 SD. Statistics are
calculated by a two-tailed Student’s t test. *** p< .001
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transduction with TGF-b CAR would not lead to the preferential
expansion of Treg cells, and the presence of any TGF-b CAR-Treg cells
is unlikely to induce suppressive effects on the activity of tumor-
targeting Teff cells.
4 | DISCUSSION
In light of the recently reported clinical utility of shielding adoptive T-
cell therapies from TGF-b,13 further exploration of TGF-b counter-
measures are warranted. We previously demonstrated that TGF-b–
binding CARs can be engineered to rewire Teff cells to proliferate and
produce immunostimulatory cytokines in response to soluble TGF-b,
effectively inverting an immunosuppressive signaling molecule to a
potent T-cell stimulant that triggers immunosupportive functions.14
Here, we examined how this signal inversion impacts other immune
cells that may be found in the tumor microenvironment. We showed
that TGF-b CAR-T cells can support anti-tumor immune functions by
preserving the cytotoxicity of tumor-targeting T cells and thwarting the
differentiation of bystander T cells into the regulatory phenotype. Fur-
thermore, our results demonstrated that the production of TGF-b
CAR-T cell products for cancer therapy will not be impaired by the
presence of contaminating Treg cells. Specifically, we found that the
short (and more potent) TGF-b CAR does not express well in Treg cells
and that Treg cells expressing the long TGF-b CAR do not exert immu-
nosuppressive effects on Teff cells.
Our experiments showed that at least two mechanisms may con-
tribute to the ability of CD41 TGF-b CAR-T cells to counter the immu-
nosuppressive effect of TGF-b on CD81 cytotoxic T cells. First,
experiments with the TGF-b DNR in the CD20 CAR/Raji system
showed that increasing the capacity of CD41 T cells to bind and
sequester TGF-b can reduce TGF-b–induced suppression of CD81
cytotoxic T cells (Figures 1c,e). Consistent with past studies using solu-
ble TGF-b–binding proteins, we observed that simple sequestration of
TGF-b can, in some contexts, significantly reduce its immunosuppres-
sive potential.10,33 In addition to limiting TGF-b signaling in immune
cells, TGF-b sequestration may also reduce TGF-b’s ability to promote
tumor metastasis via mechanisms such as induction of the epithelial-
mesenchymal transition.34 In comparison to the TGF-b DNR, the TGF-
b CAR provided superior support of anti-tumor functions in both the
CD20 CAR/Raji and NY-ESO-1 TCR/M407 experimental systems (Fig-
ure 1c–f). This additional anti-tumor function may arise from the pro-
duction of immunostimulatory cytokines by activated TGF-b CAR-T
cells,14 which could support not only the engineered CAR-T cells but
also endogenous tumor-specific cytotoxic lymphocytes. Immunostimu-
latory cytokines produced by TGF-b CAR-T cells may also directly con-
tribute to reducing tumor cell numbers, as TNF-a and IFN-g have been
associated with restricted tumor cell growth.35 Importantly, in the in
FIGURE 5 TGF-b CAR expression and stimulation does not result in preferential expansion of FOXP31 Tregs among CD41/CD25hi/
CD127--sorted cells. (a) TGF-b CAR-transduced or untransduced CD41/CD25hi/CD127--sorted cells were expanded with Dynabeads only
or Dynabeads plus 5 ng/mL TGF-b for 20 days. Shown are representative scatterplots of FOXP3 versus CD25 expression corresponding to
each transduction and expansion condition. (b) FOXP3 mean fluorescent intensity (MFI) and frequency of FOXP31 cells corresponding to
each transduction and expansion condition. Averages of triplicates are shown in (b), with error bars representing61 SD. Statistics are calcu-
lated by two-tailed Student’s t test with the Sidak correction for multiple comparisons. * p< .05 and ** p< .01
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vivo tumor microenvironment, which includes other cell types absent
from our experiments, immunostimulatory cytokines may recruit addi-
tional anti-tumor mechanisms such as the polarization of macrophages
and stromal cells toward proinflammatory phenotypes.36,37 Therefore,
the anti-tumor contribution of TGF-b CAR-T cells may be further
enhanced in the more complex in vivo milieu. In vitro experiments that
incorporate additional cell types or in vivo experiments with immuno-
competent animals would be necessary to fully explore the impact of
TGF-b CAR-T cells on the tumor microenvironment.
In this study, we also explored whether the presence of Tregs may
affect TGF-b CAR-T cell production. Most published manufacturing
protocols for anti-tumor T cells have not found it necessary to specifi-
cally deplete Tregs.28–31 However, it was unclear whether TGF-b CAR-
T cell production might be uniquely challenging. Since the CAR
responds to TGF-b, a cytokine known to be produced by activated
Treg cells, this posed the theoretical possibility that TGF-b–secreting
Tregs that also express the TGF-b CAR could enter a positive-feedback
loop driven by self-activation. Furthermore, while Tregs are typically
ignored as a negligible (1%–2%) proportion of PBMCs in healthy
donors,38 the frequency of Tregs can vary greatly across individuals.
High initial Treg frequencies may be of particular concern in cancer
patients, where tumor cells have the potential to induce Treg differen-
tiation.39,40 Our results show that while TGF-b CAR-Tregs can respond
to TGF-b, they do not hinder the proliferation of Teff cells and do not
interfere with the stimulation of anti-tumor T cells.
Regulatory T cells have been engineered to express a variety of
CARs targeting immobilized antigens for the purpose of combating
autoimmune pathological processes, and CAR signaling triggered by
surface-bound antigens has been shown to induce Tregs to proliferate,
secrete immunosuppressive cytokines (including TGF-b), and repress
immune cell activities.41–46 Results from our present study showed
that soluble antigen can also be used to help trigger CAR-Treg cell pro-
liferation (Figure 7b). However, TGF-b CAR-Treg cells do not suppress
neighboring Teff cells in response to TGF-b (Figure 7c). It is possible
that TGF-b CAR-Treg cells are ineffective at suppressing Teffs because
they sequester the immunosuppressive TGF-b that they produce.
However, this hypothesis is blunted by the observation that TCR-
stimulated TGF-b CAR-Treg cells were able to inhibit neighboring Teff
cells (Figure 6a), indicating that TGF-b CAR expression alone does not
eliminate Tregs’ suppressive potential. Furthermore, TGF-b production
is only one of several mechanisms by which Treg cells can mediate
immunosuppression.47 An alternative possibility is that the absence of
contact-mediated Treg activation limits the recruitment of contact-
dependent immunosuppression mechanisms that are important in
Treg-mediated immunosuppression.48 While the exact mechanism that
underlies the lack of suppressive activity in TGF-b CAR-activated Tregs
FIGURE 6 TGF-b CAR-transduced CD41/CD25hi/CD127–-sorted cells are suppressive when stimulated through the TCR. (a) CFSE-labeled
CD41 Teffs that were not previously activated in vitro were cultured in OKT3-coated wells with CD28 agonist antibody and either 0 or 5
ng/mL TGF-b, with or without the addition of TGF-b CAR-transduced CD41/CD25hi/CD127–-sorted cells (referred to as TGF-b CAR-Tregs)
at 1:1 Treg:Teff ratio. Representative histogram overlays of CFSE dilution are shown. (b) Co-cultures were set up as described in (a), except
all wells received Tregs that were either untransduced or transduced with the TGF-b CAR. Representative histogram overlays of CFSE dilu-
tion are shown
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remains to be elucidated, our results clearly demonstrate that inadver-
tent generation of TGF-b CAR-Treg cells in a TGF-b CAR-T cell prod-
uct is unlikely to introduce counterproductive immunosuppression.
5 | CONCLUSION
This study finds that TGF-b CAR-T cells can aid anti-tumor immune
functions by shielding neighboring immune cells from the immunosup-
pressive effects of TGF-b. We further demonstrate that potential
clinical translation of the TGF-b CAR will not require additional efforts
to minimize the Treg compartment, as TGF-b CAR-expressing Tregs do
not exhibit TGF-b–induced immunosuppression. Our results support
the use of the TGF-b CAR to rewire T-cell responses to TGF-b and
reinforce cytotoxic immune functions in adoptive T-cell therapy.
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